Basic Information
| LncRNA/CircRNA Name | LINC01016 |
| Synonyms | LINC01016 |
| Region | GRCh38_6:33867506-33896914 |
| Ensemble | ENSG00000249346 |
| Refseq | NR_038989 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | endometrial cancer |
| ICD-0-3 | NA |
| Methods | qRT-PCR, Western blot, Luciferase reporter assay, in vitro knockdown |
| Sample | endometrial cell lines (Ishikawa and RL-95-) |
| Expression Pattern | up-regulated |
| Function Description | LINC01016 was substantially upregulated in endometrial cancer tissues,and LINC01016 silencing abolished the malignant behavior of endometrial cancer cells.LINC01016 positively rescued the downstream gene nuclear factor YA (NFYA) by competitively sponging miR-302a-3p and miR-3130-3p.In turn, these two miRNAs could inhibit LINC01016 transcription,thus forming two reciprocal repression cycles,which influenced the biological behavior of endometrial cancer cells. miR-3130-3p could specifically bind with the 3'-UTR regions of NFYA, and NFYA could upregulate the expression of special AT-rich sequence-binding protein 1 (SATB1) as a transcriptional factor. |
| Pubmed ID | 29467441 |
| Year | 2018 |
| Title | LINC01016 promotes the malignant phenotype of endometrial cancer cells by regulating the miR-302a-3p/miR-3130-3p/NFYA/SATB1 axis. |
External Links
| Links for LINC01016 | GenBank HGNC NONCODE |
| Links for endometrial cancer | OMIM COSMIC |